Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tarsus PharmaceuticalsTARS -1.01%46 Days Payable is 242.09 as of Jun. 2026, which is 46% below its 10-year median of 447.94. GuruFocus rates TARS with a GF Score™ of 46/100 and a GF Value™ of $160.53 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 703 Biotechnology companies, Tarsus Pharmaceuticals ranks better than 70.13% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Tarsus Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (TARS) has a Days Payable of 242.09 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tarsus Pharmaceuticals and its competitors. This is 46% below median its historical median of 447.94. Over the past decade, Tarsus Pharmaceuticals' Days Payable has ranged from 153.49 to 2,665.90. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #210 out of 703 companies in the Biotechnology industry, placing it in the top 29.9%.
Is Tarsus Pharmaceuticals' Days Payable too high?
Tarsus Pharmaceuticals' current Days Payable of 242.09 is 46% below median its 10-year median of 447.94. Over the past 10 years, this metric has ranged from a low of 153.49 to a high of 2,665.90. The Biotechnology industry median Days Payable is 112.61. Tarsus Pharmaceuticals' value of 242.09 is 115% above this industry median. Based on the distribution chart, Tarsus Pharmaceuticals ranks #210 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tarsus Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Days Payable compare to VERA and BEAM?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #210 out of 703 companies for Days Payable. This puts Tarsus Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 112.61. Tarsus Pharmaceuticals' value of 242.09 is 115% above this benchmark. Historically, Tarsus Pharmaceuticals' own Days Payable has ranged from 153.49 to 2,665.90 over the past decade. While the company's 10-year median is 447.94 vs. the industry median of 112.61, Tarsus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.61, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsus Pharmaceuticals's current Days Payable of 242.09 is 115% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current Days Payable is 242.09, which is 46% below median its own 10-year median of 447.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Significantly Undervalued. The stock's GF Value™ is $160.53, compared to a current price of $64.82 — trading 59.6% below its estimated fair value. The current Days Payable is 242.09, which is 46% below median its 10-year median of 447.94 and 115% above the Biotechnology industry median of 112.61. Tarsus Pharmaceuticals' overall GF Score™ is 46/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Days Payable is 242.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $64.82 is trading 59.6% below its estimated GF Value™ of $160.53.
GuruFocus considers Tarsus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for TARS:
Days Payable: 242.09 (46% below median its 10-year median of 447.94)
GF Value™: $160.53 vs. price of $64.82 (59.6% below fair value)
Industry Position: 115% above the Biotechnology median (#210 of 703)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
46GF Score
Get the complete analysis for TARS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
